Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$377.58 USD

377.58
972,333

+1.21 (0.32%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $377.57 -0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Globus Medical (GMED) Lags Q4 Earnings, Beats on Revenues

by Zacks Equity Research

Globus Medical (GMED) registers impressive growth within U.S. Spine on record recruiting of competitive representatives in Q4.

Zacks Equity Research

NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

NuVasive's (NUVA) Biologics business returns to growth in the fourth quarter of 2019.

Zacks Equity Research

Syneos Health (SYNH) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

We are upbeat about the strong year-over-year revenue growth in the Clinical Solutions segment of Syneos Health (SYNH) in Q4.

Zacks Equity Research

Henry Schein (HSIC) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Henry Schein (HSIC) registers solid performance by each of its key operating businesses in Q4.

Zacks Equity Research

Bruker (BRKR) Stock Rises on Strong Preliminary Q4 Show

by Zacks Equity Research

Bruker's (BRKR) revenue growth is expected to beat expectations for the fourth quarter and 2019.

Sheraz Mian headshot

Q4 Earnings Scorecard and Analyst Reports for NVIDIA, Costco & Stryker

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), Costco Wholesale (COST) and Stryker (SYK).

Zacks Equity Research

Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Amedisys' (AMED) fourth-quarter earnings benefit from solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.

Zacks Equity Research

Chemed (CHE) Q4 Earnings & Revenues Beat Estimates, Margins Up

by Zacks Equity Research

Chemed's (CHE) fourth-quarter 2019 results reflect strong segmental performances.

Zacks Equity Research

Ecolab (ECL) Earnings and Revenues Miss Estimates in Q4

by Zacks Equity Research

Strength in the Global Industrial arm drives Ecolab's (ECL) Q4 results.

Zacks Equity Research

Medtronic (MDT) Q3 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

Medtronic (MDT) demonstrates better-than-expected Q3 performances at CER, backed by growth in all major business segments and geographies.

Zacks Equity Research

Here's Why You Should Retain Haemonetics in Your Portfolio Now

by Zacks Equity Research

Haemonetics (HAE) witnesses high investor confidence on solid prospects.

Zacks Equity Research

Cardiovascular Systems Grows on Domestic Sales Amid Margin Woe

by Zacks Equity Research

Cardiovascular Systems (CSII) continues to register solid top-line growth on strength in the domestic atherectomy businesses.

Zacks Equity Research

Myriad Genetics (MYGN) Releases Favorable Prolaris Results

by Zacks Equity Research

This study result is a major breakthrough and is expected to strengthen Myriad Genetics' (MYGN) Oncology segment.

Zacks Equity Research

Change Healthcare (CHNG) Q3 Earnings Top Estimates, Down Y/Y

by Zacks Equity Research

Change Healthcare's (CHNG) third-quarter fiscal earnings benefit from solid performance across the segments - Software and Analytics and Network Solutions. However, decline in revenues remains a woe.

Zacks Equity Research

DexCom (DXCM) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter earnings benefit from higher revenues and solid performing Sensor and Transmitter segments.

Zacks Equity Research

Bio-Rad (BIO) Q4 Earnings & Revenues Fall Short of Estimates

by Zacks Equity Research

Bio-Rad's (BIO) fourth-quarter 2019 results reflect strong segmental performances.

Zacks Equity Research

AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) Q4 results gain from core Nurse and Allied Solutions units.

Zacks Equity Research

LabCorp's (LH) Q4 Earnings Beat Estimates, Margins Rise

by Zacks Equity Research

LabCorp (LH) registered year-over-year growth in operating segments in Q4.

Zacks Equity Research

Ares Management (ARES) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Ares Management (ARES) delivered earnings and revenue surprises of 34.00% and 14.03%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myriad Genetics (MYGN) Files for myChoice CDx Test sPMA

by Zacks Equity Research

With the receipt of the regulatory approval, Myriad Genetics (MYGN) will be taking a major stride forward in its Oncology and Women's Health segment.

Trina Mukherjee headshot

3 Medical Product Stocks Likely to Beat This Earnings Season

by Trina Mukherjee

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Zacks Equity Research

Sonoco (SON) Meets Q4 Earnings Estimates

by Zacks Equity Research

Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CVS Health (CVS) Q4 Earnings Top Estimates, Margins Improve

by Zacks Equity Research

CVS Health (CVS) registers strong growth in Pharmacy Services, benefiting from the upside in specialty services.

Urmimala Biswas headshot

Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More

by Urmimala Biswas

Strong foothold in the emerging markets so far widely contributes to some of the industry players' Q4 results.

Zacks Equity Research

Exact Sciences (EXAS) Q4 Earnings and Revenues Rise Y/Y

by Zacks Equity Research

Exact Sciences' (EXAS) fourth-quarter 2019 results reflect strong segmental performances.